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ABSTRACT 
 
The occurrence of chemicals of natural origin that possess the capacity to mimic the 
hormonal properties of estrogen has been previously reported in the biomedical literature. From 
these reports, it is apparent that the structural nature of these estrogen mimics is very diverse. This 
estrogen mimic can be found in plants used in the treatment of health conditions as alternative 
medicine, such as the treatment of symptoms associated with menopause. Many of these plants 
have been investigated, but there still exist many instances in which estrogenic activity is 
unsuspected and exposure unknown. 
This research focuses on Trigonella foenum-graceum (Fabaceae), commonly known as 
Fenugreek, which has been used since antiquity as a galactogogue to increase milk production in 
nursing women. It has been suggested that Fenugreek contains phytoestrogens responsible for this 
galactogogic activity. Although previous reports support Fenugreek’s estrogenic activity and many 
of its complex chemical constituents have been elucidated, no specific chemical responsible for 
the purported estrogenic activity has been identified with certainty. The objective of this 
investigation is to study the chemistry of Fenugreek for estrogenic activity and using a bioassay-
guided approach to isolate and elucidate principle(s) associated with the putative hormonal 
activity. 
For the chemical and estrogenic study of Fenugreek, seeds were ground up and extracted 
with organic solvents of various polarities. Further fractionation of extracts was performed with 
the use of Sephadex LH-20 column chromatography and preparative Thin Layer Chromatography 
(TLC). The chemistry in these extracts has been explored using TLC and various diagnostic spray 
reagents for composition profiles. These crude extracts were used to test for estrogenic activity 
and further chemical elucidation. The estrogenic activity was assayed using the strain YGY13 of 
Saccharomyces cerevisiae transformed with the plasmid pGEV-HIS3, which contains the human 
estrogen receptor and a -galactosidase reporter gene. Initial investigation of Fenugreek revealed 
the presence of the steroidal saponin Diosgenin in the active chloroform/methanol extract as shown 
by the use of the Liebermann-Burchard reagent and an authentic sample, as well as, the use of 
mass spectrometry. Sequential bioassay guided fractionation of this extract revealed the presence 
of additional non-steroidal estrogenic constituents resulting in the detection by mass spectrometry 
of a family of isoflavones. This is the first time that the presence of these isoflavones in Fenugreek 
have been directly associated with its estrogenic activity. 
The Acetylcholinesterase inhibition activity of Fenugreek was explored using an in vitro 
bioautographic method on TLC, and the antibiotic properties were assayed against yeast as a test 
organism. Extracts of fenugreek were found to possess both pharmacologic activities. 
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Chapter 1 
Estrogenic Activity 
I. Introduction 
 
 Hormones play diverse regulatory roles, effecting blood pressure, electrolyte balance, 
embryogenesis, sexual differentiation, development and reproduction, just to name a few. 
Hormones have a diverse chemical nature such as peptides, catecholamines, eicosanoids, steroids, 
and retinoids. Thus hormones have diverse functions, as well as diverse structures. A particular 
class, steroidal hormones, also known as adrenocortical and sex hormones, reach their target cells 
by binding to circulating plasma proteins traveling through the bloodstream and act through 
nuclear receptors in the cell to change the level of expression of a certain gene (Ackerman & Carr, 
2002). The relatively small and lipophilic nature of steroids allows them to easily pass through the 
cellular plasma membrane to bind to intracellular receptors. The steroid hormones, including 
progesterone, cortisol, aldosterone, testosterone and estradiol, are synthesized from cholesterol in 
many of the endocrine tissues (Nelson and Cox, 2000). 
One of the most widely discussed types of steroidal hormones are estrogens. The principal 
estrogens are estrone, estradiol, estriol and catechol metabolites, which are shown in Figure 1. The 
effects of estrogen are mediated by two estrogen receptor subtypes, ERα and ERβ, which are 
differentially sensitive to various estrogens. Some estrogenic molecules can be full agonists for 
one of the receptors while being full antagonists for the other receptor (Ketzenellenbogen et al. 
2000). This further illustrates the complexity of estrogen and its physiological effects. Estrogens 
affect the female reproductive system, regulation of skeletal homeostasis, lipid and carbohydrate 
metabolism, electrolyte balance, skin physiology, the cardiovascular system and the central 
nervous system (Hall, 2011; Nilsson & Gustafsson, 2011; Vrtačnik et al. 2014). Consequently, 
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estrogen affects both males and females in several different manners. Not only is the presence of 
estrogen necessary for proper physiological function, but the long-term deficiency of estrogen can 
cause osteoporosis, cardiovascular disease, and possibly Alzheimer’s disease (Harlow & 
Signorello, 2000). As a result, there might be instances in which there could be reasons why one 
would want to take estrogen or estrogen-like compounds for medicative or preventative purposes.  
 
Figure 1. The main estrogens and metabolites in women (Ackerman & Carr, 2002) 
 
 For instance, many women turn to herbs and plant extracts as an alternative to hormone 
replacement therapy (HRT) and estrogen replacement therapy (ERT) because of their undesirable 
side effects, such as increased risk of breast and endometrial cancer and irregular bleeding (Sreeja 
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et al. 2010). Such an alternative is the case of Black Cohosh (Actaea racemosa, Ranunculaceae) 
used in the treatment of symptoms associated with menopause or the soy derived products that 
were recently found to contain estrogenic isoflavones (Newton et al. 2006). Although Black 
Cohosh was a very popular herbal medicine for women’s reproductive health in the 19th century, 
several studies have concluded that Black Cohosh lacks an estrogenic mechanism of action and its 
efficacy in treating menopausal symptoms is doubtful (Peng et al. 2014; Ross, 2014). This raises 
the concern of the validity of the use of herbal medicines with purported estrogenic activity and 
issue as to whether or not some ethnobotanical claims need to be scientifically tested. 
On the other hand, there is much more certainty with soy. Soy contains the isoflavones 
genistein, daidzein and glycitein, which are non-steroidal compounds that exhibit estrogen-like 
properties, shown in Figure 2 (Messina & Wood, 2008). These isoflavones preferentially bind to 
ERβ, which classifies them as selective estrogen receptor modulators (SERM) and they exhibit 
weak estrogen-like effects under certain experimental conditions (Ye et al. 2009). Recent evidence 
suggests that soy isoflavones reduce the risk of breast cancer, which could be because the binding 
of isoflavones to estrogen receptors blocks the action of the stronger endogenous estrogen binding 
on these receptors (Blei et al. 2015; Breast Cancer and Environmental Risk Factors, 2002). 
Despite controversy over isoflavones and their relationship to breast cancer, it is accepted that soy 
contains natural chemicals that mimic the hormonal properties of estrogen. These type of 
molecules are referred to as phytoestrogens. 
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Figure 2. A structural comparison of the phytoestrogens genistein and daidzein 
found in soy to estradiol. The 15-carbon structures of these phytoestrogens is 
similar to the 17-carbon structure of estradiol, as shown above. (Notelivitz et al. 
2003) 
 
 
Phytoestrogens are molecules present in certain plants that are structurally and functionally 
analogous to endogenous human estrogen (Jargin et al. 2014). They have the potential to act as 
estrogen agonists or antagonists, which could interfere with the proper functioning of the endocrine 
system (Mortel & Mehta, 2013). When seeking out phytoestrogens, plants used as galactagogues 
are a promising source. Galactogogues are substances that assist the initiation, continuation, or 
augmentation of breast milk production that may act via the estrogen receptor (ER) to stimulate 
the female reproductive system (Academy of Breastfeeding Medicine Protocol Committee, 2011). 
The galactogogue effect associated with estrogen is believed to be caused by its stimulating effect 
on the ductal epithelial cells or the potentiation of prolactin production (Mortel & Mehta, 2013). 
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Such is the case for Asparagus racemosus, or shatavari, a plant used as a galactagogue in India. 
Studies have demonstrated the plant’s estrogenic effects in the mammary glands and genital organs 
of rats, which are thought to be caused by the presence of phytoestrogens in the form of saponins 
and steroidal saponins in shatavari roots (Gupta & Shaw, 2011).  
The use of galactagogues like shatavari is widespread, with many clinicians recommending 
the use of herbs to improve milk output. An estimated 15% of breastfeeding women use herbal 
galactogogues in the United States and 43% in Norway, however there is limited evidence on the 
mechanism of action behind these herbs and their galactogogue properties (Mortel & Mehta, 2013; 
The National Children’s Study, 2003; Nordeng & Havnen, 2004). While some of the reported 
galactogogue effects may be linked to phytoestrogens, it is likely that there are many different 
mechanisms of action involved in the efficacy of these plants.  Fenugreek, or Trigonella foenum-
graceum (Fabaceae), is the most commonly used over the counter (OTC) herbal galactagogue in 
published literature, yet the mechanism of action and exact compound(s) behind its reported 
lactation enhancing activity is unclear (Mortel & Mehta, 2013). However, since Fenugreek has not 
only been used as a galactogogue, but also for its hypocholesterolemic, aphrodisiac and 
hypoglycemic activities among many others, compounds exhibiting hormonal activity like 
phytoestrogens may be present (Parthasarathy et al. 2008). Estrogenic activity of Fenugreek seeds 
was confirmed by Sreeja et al. in a study in which MCF-7 cells were treated with a chloroform 
extract of the seeds. This resulted in the discovery that molecules in the extract bind to the ER and 
act as an agonist for ER mediated transcription (Sreeja et al. 2010). 
Despite studies that have confirmed Fenugreek’s estrogenic activity, there is still 
conflicting evidence on its efficacy (Mortel & Mehta, 2013). Currently, the most supported 
hypothesis for Fenugreek’s reported estrogenic activity is the presence of diosgenin in Fenugreek 
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seeds, which is the main natural steroidal sapogenin used in the commercial manufacture of 
steroidal drugs like cortisone and sexual hormones (Mortel & Mehta, 2013; Brenac & Sauvaire, 
1996; Kang et al. 2013, Chan & O’Malley, 1976). However, there are many other steroidal 
saponins present in Fenugreek that have the potential to be structurally similar to endogenous 
estrogen (Kang et al. 2013, Chan & O’Malley, 1976). Furthermore, Fenugreek has diverse 
chemistry that goes beyond steroidal saponins like flavonoids, coumarin compounds and alkaloids 
which could contribute to its estrogenic activity (Chan & O’Malley, 1976). Reported flavonoids 
present in Fenugreek include vitexin, tricin, naringenin, quercetin, kaempferol, and luteolin, shown 
in Figure 3 (Parthasarathy et al. 2008). One study even reports the presence of the isoflavones 
daidzein and genistein in Fenugreek, however this finding is not well documented in the scientific 
literature and needs to be confirmed (Kaur, 1998).  
 
Figure 3. Flavonoids found in Fenugreek (Parthasarathy et al. 2008) 
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 Overall, Fenugreek is a good candidate for a plant possessing phytoestrogens. Its 
widespread uses may imply that a hormonal modulator is at play and its diverse chemistry gives a 
robust collection of compounds with the potential to exhibit estrogenic activity, which has been 
confirmed various times. Nonetheless, the exact chemistry behind this reported estrogenic activity 
is ambiguous and may be due to the synergistic effect of several different phytoestrogens that 
include saponins, isoflavones, or other chemical compounds. The elucidation of phytoestrogens in 
Fenugreek bears significance in both the pharmaceutical and toxicological realms of science since 
estrogens exhibit such a broad range of effects in humans. Although this study does not focus on 
the toxicology of phytoestrogens, as with any therapeutic use of a plant, the toxicology of a plant 
must be taken into consideration. This study can be used to alert the potential adverse effects of 
Fenugreek in individuals sensitive to estrogen exposure, like certain Breast Cancer 
patients/survivors, and raise awareness for safer medicinal uses of Fenugreek based on this 
particular endocrinopharmacology (Patiaul & Jefferson, 2013). 
Nevertheless, the aim of this investigation is to isolate the chemical compound(s) 
responsible for Fenugreek’s purported estrogenic activity utilizing an estrogen activity reporting 
biological system to guide the fractionation of active crude extracts.  
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II. Methods and Materials  
i) Plant Processing 
Commercial seeds of Fenugreek (Trigonella foenum-graecum, Fabaceae) were 
obtained from Greenstar Coop. Natural Foods Market in Ithaca, NY. The Fenugreek 
seeds used for a comparative analysis to chemical composition between cultivars were 
obtained from Wegmans in Ithaca, NY.  The seeds (250g) were finely ground in a 
Waring blender and transferred into a flask with 1.5L of Hexane. The flask was placed 
on a magnetic stirring plate for two days for extraction. After two days the Hexane 
solution was filtered by gravity into an Erlenmeyer flask using Whatman No. 1 filter 
paper. The filtrate was collected as the hexane extract and the filter papers with the 
solid residue were allowed to dry in a fume hood. The filtrate was evaporated to dryness 
in a Buchi RII Rotary Evaporator, the yield of the dried hexane extract calculated, and 
the residue re-suspended in Hexane. A hexane fenugreek extract (HFG) at a 
concentration of 235.4 g/L resulted from this extraction. To approximate the molar 
concentrations of the extracts, the average molecular weight of the compounds was 
assumed to be 250g/mol. Consistent with Lipinski’s rule, it has been proved from a 
drug-like natural product library of 126,140 compounds that the average molecular 
weight of natural products, like the secondary metabolites being isolated in fenugreek, 
have an average molecular weight of 250g/mol (Quinn et al. 2008). Once the solid seed 
residue was dried, the same extraction procedure was followed in subsequent 
extractions using a semi-polar solvent mixture of 1:1 Chloroform/Methanol and then a 
polar solvent of 70% aqueous ethanol. This resulted in a chloroform/methanol 
fenugreek extract (CMFG, 129.6 g/L) and an aqueous ethanol fenugreek extract 
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(AEFG, 312 g/L). Further fractionation of the semi-polar extraction was performed by 
partitioning the extract into a methanol soluble portion and a chloroform soluble 
portion. This was done by evaporating the CMFG extract to dryness and mixing the 
dried residue with methanol in the rotary evaporator for 30min over in a 30⁰C water 
bath. This solution was then filtered and evaporated to dryness. The same procedure 
was performed again, but with chloroform as the solvent. The resulting fractions were 
262.5g/L and 76g/L for the methanol soluble portion (mFG) and chloroform soluble 
portion (cFG) respectively. 
ii) Thin Layer Chromatography Analysis 
Silica gel Thin Layer Chromatography (TLC) was used to profile the chemical 
composition in various extracts and diagnose for the presence of specific compounds 
using various spray reagents. TLC Silica gel 60 F254 5X10cm glass plates (Merck, 
Germany) were used to perform the chromatography. The main solvent system used 
was ethyl acetate/methanol/water (10:2.7:2). Various visualization and diagnostic 
spray reagents were used on the TLCs (i.e., UV light short/long wavelength, vanillin, 
FeCl3, iodine). The Liebermann-Burchard reagent (5mL acetic anhydride, 2.5mL 
sulphuric acid, 2.5mL ethanol) was used to detect the presence of steroidal compounds. 
iii) Ferric Chloride Diagnostic Test 
The ferric chloride spray reagent was used as a diagnostic test for phenols. Ferric 
Chlordie (0.25g) and 95% aqueous ethanol 925mL) were mixed to create the spray 
reagent. The reagent was sprayed onto developed TLC plates to test for the presence of 
phenols. Since ferric chloride is an oxidizing and chelating agent, it causes a color 
change with the presence of phenolic compounds by the production of a coordination 
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complex formed between the iron(III) and three phenolate ions (Mohrig et al. 2003). 
Not all phenols produce colored complexes under test conditions, but if a color change 
is apparent, a phenol is present. The only exception to this observation is the 
development of a blue dark color caused by certain non-phenolic compounds. Apart 
from this exception, catechols produce a green color with the ferric chloride spray 
reagent, phenols with H-bonded OH groups produce a purple color and highly acidic 
phenolic OH groups give a brown color (Krishnaswamy, 1999). 
iv)  Column Chromatography Fractionation of Crude Extracts 
A Sephadex LH-20 Lipophilic size-exclusion column chromatography was used to 
fractionate the mFG extract using methanol as the eluent. Eight fractions resulted from 
this fractionation according to their molecular size. The different bands were 
distinguished by color under visible light and their fluorescence, if any, under a portable 
UV lamp. The fractions resulting from this column have been assayed for estrogenic 
activity. 
v) Preparative Thin Layer Chromatography 
Preparative Thin Layer Chromatography (TLC) was used to separate the distinct 
bands present on the TLC for mFGcons. A Silica gel 60 F254 20x20cm glass plate 
(Merck, Germany) was used to separate the compounds in mFGcons using an ethyl 
acetate: methanol: water (10:7:2) solvent system. After the TLC was developed in a 
glass chamber, a pencil was used to indicate the bands that had been separated and the 
silica gel was etched off of the glass plate using a chisel for each band. Each of the sets 
of chiseled silica gel were ground to powder using a mortar and pestle, dissolved in 
methanol, and filtered through a Whatman No. 1 filter paper.  
14 
 
vi) Yeast Transformation to Construct a Strain that Expresses the Human Estrogen 
Receptor  
The yeast strain, Saccharomyces cerevisiae, YGY13 (MATa ade1 leu2-3, 2-
112::UASGAL10-lacZ- LEU2 his3∆ gal4∆ ura3-52) was transformed with plasmid 
pGEV-HIS3 (Gao, 2000) using the “lazy bones” plasmid transformation of yeast 
colonies protocol described in Burke et al. (2000).  Briefly, a single yeast colony was 
incubated with 1 µg plasmid pGEV-HIS3 and 100 µg herring sperm DNA in PLATE 
solution (40% polyethylene glycol (MW 3350), 0.1 M lithium acetate, 10 mM Tris-
HCl pH 7.5, and 1 mM EDTA) containing dimethyl sulfoxide at 30 °C for 15 min and 
heat shocked at 42 °C for 15 min.  Cells were subsequently pelleted, re-suspended in 
water, and plated on chemically defined growth medium lacking 
histidine.  Transformants were isolated after incubation at 30 °C for 3 days and used to 
inoculate experimental cultures.  
 
vii) Quantification of Estrogenic Activity using a β-galactosidase Reporting Assay 
The estrogenic activity is measured as β-Galactosidase activity using the 
commercial β-Galactosidase Assay Kit (Thermo Scientific). To run the assay, 
transformed yeast cells were grown overnight in test tubes with an I⁺-His medium in a 
shaker incubator at 30⁰C. Then, the OD of the cultures was measured at 600nm in a 
UV-vis spectrophotometer and cultures were diluted back to an OD of around 0.4. 
Theses test tubes were then placed back in the incubator until the cells reached an OD 
between 1.0 and 1.5, or the exponential phase of yeast cell growth. Once the cells 
reached this point, they were ready to be used in the β-galactosidase Assay. For each 
assay performed, an estradiol (100nM) treatment was used as a positive control and a 
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water treatment was used as the control. Other materials used in this assay include a 
water bath at 37⁰C, Eppendorf tubes, pipettes, vortex mixer, centrifuge and the Y-PER 
Yeast Protein Extraction Reagent, 2X β-Galactosidase Assay Buffer, and β-
Galactosidase Assay Stop Solution. Final absorbance of the samples at 420 nm was 
measured and β-Galactosidase expressed as Miller Units. β-Galactosidase 
measurements are interpreted as estrogenic activity measurements. The following 
equation is used to calculate estrogenic activity in Miller units (Instructions: β-
Galactosidase Assay Kit, 2012). 
𝛽𝑔𝑎𝑙𝑎𝑐𝑡𝑜𝑠𝑖𝑑𝑎𝑠𝑒 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
1,000 ∗ 𝐴420
𝑡 ∗ 𝑉 ∗ 𝑂𝐷660
 
𝑡 = 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛 = 15𝑚𝑖𝑛 
𝑉 = 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑢𝑠𝑒𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑎𝑠𝑠𝑎𝑦 = 2.5𝑚𝐿 
𝐴420 = 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑠 𝑎𝑡 420𝑛𝑚 
𝑂𝐷660 = 𝑜𝑝𝑖𝑡𝑐𝑎𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 
 
viii) Electrospray Ionization Tandem Mass Spectrometry (ESIMS/MS) Analysis 
Mass spec work was done at Cornell University at the Proteomics and Mass 
Spectrometry Facility at the Institute of Biotechnology. Samples were prepared for 
ESIMS/MS at appropriate concentrations and cleaned from particulates with the aid of 
a syringe filter (PTFE or Nylon respectively; 0.2 mm, Alltech). The samples were 
analyzed in the negative ion mode using Electrospray Ionization Tandem Mass 
Spectrometry (ESIMS/MS) in a 4000 Q Ion Trap LC/MS (Applied Biosystems) 
spectrometer, at an infusion rate of 10ml/hr and a capillary voltage of ±3500V. Mass 
spectra were acquired and selected parent ions were subjected to MS/MS analysis. 
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ix) Statistics 
The statistical software Matlab R2014a, The MathWorks, Inc. (Natick, 
Massachusetts, United States) was used to perform statistical analysis on the data. A 
two sample t-test was used to compare estrogenic activity between samples, using the 
function “ttest2”. Results were considered statistically significant if p<0.05 or 
otherwise noted. Microsoft Excel 2013 (Redmond, Washington) was used to calculate 
the standard error of the estrogenic activity of samples. 
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III. Results and Discussion 
To establish the putative estrogenic activity of fenugreek seeds, crude extracts were 
prepared using organic solvents with increasing polarity. Three extracts were prepared, a non-polar 
extract using hexane (HFG), an intermediate polarity extract with a mixture of 
chloroform/methanol (1:1) (CMFG), and a polar extract prepared with 70% aqueous ethanol 
(AEFG). 
The outline of the investigation is detailed in Figure 4. The overarching guiding principle 
of the research process in this project was to use the biological activity of the extracts to lead to 
the chemistry associated with the estrogenic activity and ultimately elucidate the phytoestrogens 
present in Fenugreek. In this case, the estrogenic activity of extracts tested using the β-
galactosidase reporting assay was used to decide which fenugreek fractions would be pursued for 
elucidation of the chemistry responsible for the reported estrogenic activity. 
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Figure 4. Flow chart of the bioassay guided fractionation of 
fenugreek seeds to isolate chemistry with estrogenic activity. 
Estrogenic activity: (+) present, (-) absent                                                    
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Two commercial samples of fenugreek seed were purchased locally and used for the 
project. The chemical composition profiles of the hexane, chloroform/methanol and aqueous 
alcohol extracts were thoroughly compared for consistency between cultivars. The chemical 
composition of both fenugreek seeds was shown to be basically identical. To come to this 
conclusion, TLC was used exhaustively using various solvent systems and visualization techniques 
including several spray reagents. Figure 5 shows the similarity between fenugreek seeds obtained 
from two different venders. Additionally, the chemical stability of fenugreek seed constituents 
from the same vendor extracted one year apart was verified by examining old and new extracts to 
validate using samples from the previous year’s extraction in the research. Figure 6 shows the 
chemical stability of fenugreek seed constituents over this time span. Although the TLC’s of the 
new extracts were applied to the TLC plate in higher concentrations than the old extracts (evident 
by the bolder spots), the same chemical compounds appear to be present in each of the samples. 
This concludes that the chemistry present in the fenugreek seed extractions is relatively stable over 
time. 
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Figure 5. The CMFG extract purchased from Greenstar Coop. Natural Foods 
Market in Ithaca, NY (nCMFG) compared to fenugreek seeds purchased from 
Wegmans in Ithaca, NY (WCMFG). An ethyl acetate:methanol:water 
(10:2.7:2) solvent system with Liebermann-Burchard reagent applied. Plate 
viewed under normal lighting, long wavelength and short wavelength UV 
(left to right). 
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Figure 6. A comparison of two distinct Fenugreek seed extractions separated 
using an ethyl acetate:methanol:water (10:2.7:2) solvent system with 
Liebermann-Burchard reagent applied. Three extractions, HFG, CMFG, AEFG 
(from left to right), are shown on each plate. The plates are presented under 
normal lighting (top), long wavelength UV light and short wavelength UV light 
(from left to right). 
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The HFG, CMFG and AEFG extractions were tested for estrogenic activity in the β-
galactosidase reporting assay. The plasmid containing the human estrogen receptor used in the 
transformation of the yeast cells is shown in Figure 7 and the protocol for this assay is shown in 
Figure 8. The manner in which the assay functions is that if estrogen, or an estrogen mimic, is 
present in the medium the cells are growing in, it will bind to the human β-estradiol α-receptor 
(hER) that is present in the promoter region of the pGEV-HIS3 plasmid. The promotor region 
includes a vector encoding the β-estradiol inducible activator, GAL4.ER.VP16 (GEV), which is 
analogous to the steroid inducible Gal4p-directed expression systems in mammalian cells. Once 
an estrogenic compound binds to hER, the expression of GAL4 is induced. GAL4 is a protein that 
is a positive regulator for the expression of galactose-induced genes such as GAL1 and GAL10. 
The expression of these galactose-induced genes produces β-galactosidase, an enzyme generally 
used to convert galactose to glucose. In this assay, the β-galactosidase activity is measured by its 
hydrolyzing action on the substrate o-nitrophenyl-β-galactopyranoside (ONPG) that releases o-
nitrophenol (ONP), which is measured at 420nm. This produces a system in which the expression 
of β-galactosidase, and as a result, formation of ONP, is dose dependent on the amount of estrogen 
or estrogen like compounds the cells are exposed to (Gao & Pinkham, 2000). 
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Figure 7. The pGEV-HIS3 plasmid used in the transformation of yeast cells 
with the human estrogen receptor. The GEV chimera contains the following 
domains: the N-terminal 93 amino acids (aa) of Gal4p, aa 282-576 of the 
human β-estradiol α-receptor, the C-terminal 424-490 aa of VP16. The 
numbers in parenthesis indicate the positions of FspI sites in pGEV-HIS3, 
the sizes of the DNA fragments encoding the MRP7 promoter, and the 
domains of the chimeric activator in base pairs (Gao & Pinkham, 2000). 
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Figure 8. A simplified outline of the protocol used to measure 
estrogenic activity using the β-galactosidase assay. 
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In the first step of the bioassay guided fractionation of fenugreek seeds, the comparative 
assessment of the estrogenic activity of the various extracts prepared from fenugreek seeds (Figure 
9) showed higher estrogenic activity for the CMFG sample than the AEFG and HFG. The extracts 
were tested in duplicate for this assay and the estrogenic activities of HFG, CMFG and AEFG 
were found to be 13.3 Miller units/M, 18.2 Miller units/M and 7.10 Miller units/M respectively. 
The estrogenic activity of the HFG was statistically significantly different (p<0.05) from the 
CMFG with p=0.0168 as well as the AEFG, with p=0.00810. The estrogenic activity of CMFG 
compared to AEFG was not statistically significant, with a p-value of 0.0780. However, since the 
difference between the estrogenic activity of CMFG and AEFG was significant to the level of 
significance p<0.10, this was convincing enough to pursue the CMFG extract for further study. 
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Figure 9. Estrogenic activity of nonpolar (HFG), semi-polar (CMFG) and polar 
(AEFG) fenugreek extracts with the standard error shown (SE=0.257, 0.391, 
1.42, 0.398 from left to right). The estradiol standard is at a concentration of 
100nM while the extracts are at concentrations of ~1M. 
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The presence of diosgenin in fenugreek that is reported in the literature (Mortel & Mehta, 
2013; Brenac & Sauvaire, 1996; Kang et al. 2013, Chan & O’Malley, 1976) was confirmed using 
TLC analysis, diagnostic reagents for steroidal saponins (ie. Liedermann Burchard), and mass 
spectrometry. A commercial diosgenin standard (93%, Sigma Chemical Company) was used to 
compare to the HFG, CMFG and AEFG extractions. Use of the Liebermann-Buchard reagent 
guided the identification of diosgenin (Figure 10). 
 
 
 
Figure 10. A TLC of diosgenin, HFG, CMFG and AEFG extracts run 
in an ethyl acetate:methanol:water (10:2.7:2) solvent system and 
sprayed with the Liebermann-Buchard reagent. The TLC plate is shown 
under normal light and long wavelength UV light (left to right). 
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Further analysis of the CMFG extract using mass spectrometry confirmed the presence of 
diosgenin (Figure 11). The estrogenic activity of the diosgenin standard was verified (Figure 12), 
which confirms that if the CMFG extract contains diosgenin, part of its estrogenic activity is due 
to the presence of diosgenin.  
 
 
 Figure 11. The product of ion mass spectra of diosgenin. 
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Figure 12. The measured estrogenic activity of the estradiol (100nM) 
and diosgenin standards (20mM) reported using the β-Galactosidase 
Estrogenic Activity Assay. 
 
The CMFG fraction was further investigated by bioassay guided fractionation to assess 
the presence of any other additional estrogenic components. To initiate the fractionation of the 
CMFG extract, it was partitioned into its methanol soluble fraction (mFG) and chloroform 
soluble fraction (cFG) (see methods section). The composition of the CMFG extract with its 
resulting fractions is shown in the TLCs in Figure 13. However, the CMFG and cFG separated 
into two phases, a bottom phase (bp) and a supernatant phase (sp). Since the diosgenin is not 
present on the TLC in Figure 13, it is hypothesized that the diosgenin is present in the bottom 
phase of the cFG, which was not applied to the TLC.  Figure 13 shows the supernatant cFG 
(cFGsp) and mFG compared to the supernatant CMFG (CMFGsp).  
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The estrogenic activity of the cFG and mFG samples was measured using the β-
galactosidase assay. Estrogenic activities were 1.00 Miller unit/M, 1.28 Miller units/M and 0.35 
Miller units/M for CMFGsp, mFG and cFGsp respectively. Results are shown below in Figure 14. 
To qualify these results, they suggest that the estrogenic activity of CFGsp is notably reduced 
compared to CMFGsp and mFG. Since the methanol portion (mFG) reported more estrogenic 
activity than the chloroform portion (cFGsp), the estrogenically active chemistry from the CMFG 
extract was preferentially soluble to methanol and this fraction was further pursued to isolate the 
estrogenic compounds. Although there weren’t replicates produced in order to perform statistical 
CMFGsp cFGsp 
Figure 13. An ethyl acetate:methanol:water (10:2.7:2) solvent system was used with 
the Liebermann-Burchard reagent applied to visualize the cFGsp and mFG portions 
of the CMFG. Plate viewed with long wavelength UV, normal lighting, and short 
wavelength UV (left to right). 
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analyses, the main purpose of these assays is to test for the presence or absence of estrogenic 
activity in order to reach the isolation of compounds that are estrogenically active. Since all of 
these extracts possess estrogenic activity, if any of them were pursued, the isolation of 
estrogenically active compounds would be likely. However, under the time constraints, the fraction 
with the highest amount of estrogenic activity was pursued in each subsequent round of estrogenic 
activity assays. 
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Estrogenic Activity of chloroform soluble and methanol 
soluble portions of CMFG
Figure 14. Estrogenic activity of supernatant of CMFG (CMFGsp), the methanol 
soluble portion of CMFG (mFG) and the supernatant of the chloroform soluble 
portion of CMFG (cFGsp) fenugreek extracts. The estradiol standard is at a 
concentration of 100nM while the extracts are at concentrations of ~1M. 
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The mFG extract was fractionated using size exclusion Sephadex LH-20 column 
chromatography, shown in Figure 15. Based on the different bands distinguished by color under 
visible light and their fluorescence, if any, under a portable UV lamp, eight fractions resulted from 
the fractionation.  
 
mFG7, mFG8 
mFG6 
mFG3, mFG4, 
mFG5 
mFG2 
mFG1 
Figure 15. Fractionation of mFG using Sephadex column 
chromatography with methanol as the solvent system. Fractions were 
labeled mFG1-mFG8 as they exited the column. 
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Subsequently, the estrogenic activity of the methanol fractions, mFG1-mFG8, was 
determined using the estrogenic activity β-galactosidase assay. The concentration of each fraction 
was standardized to a concentration of 0.1g/mL. However, it must be taken into consideration that 
the minute amounts of methanol used to re-suspend some of the fractions and the limitations of 
the mass balance may have caused some error in the standardization of concentrations. The results 
for the estrogenic activity were as follows: mFG (9.78 Miller units/M), mFG1 (0 Miller 
units/fraction), mFG2 (0.17 Miller units/fraction), mFG3 (0 Miller units/fraction), mFG4 (0 Miller 
units/fraction), mFG5 (5.06 Miller units/fraction), mFG6 (9.03 Miller units/fraction), mFG7 (6.53 
Miller units/fraction), mFG8 (4.54 Miller units/fraction). Results are shown in Figure 16. 
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Figure 16. The estrogenic activity reported in Miller units of the mFG1-mFG8 
fractions separated from the mFG extract using size exclusion Sephadex LH-20 
column chromatography. Concentrations among the fractions were not 
standardized. 
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The chemical compositions of the fractions were then examined using silica gel TLC and 
the vanillin spray reagent to analyze the differing chemical composition of the samples (Figure 
17). As shown in the TLC’s, fractions mFG6, mFG7 and mFG8 all have very similar chemical 
components, which are also fractions that possess estrogenic activity. 
 
Figure 17. An ethyl acetate: methanol: water (10:2.7:2) solvent system used 
to separate components of the CMFG, cFG, mFG and the eight methanol 
fractions fractionated by the Sephadex LH-20 column (from left to right). 
The TLC plate on the left was examined under short wavelength UV light 
prior the application of the vanillin spray and the plate on the right was 
sprayed with the vanillin spray reagent. 
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For further chemical analysis, the estrogenic fractions mFG5, mFG6, mFG7 and mFG8 
were examined for the presence of phenolic compounds using a ferric chloride spray reagent on a 
TLC plate (Figure 18). Since a brown-green color developed for spots in the lane of each of the 
fractions on the TLC, the test was positive for phenolic compounds in all four fractions 
(Krishnaswamy, 1999; Mohrig et al. 2003).  
 
Figure 18. A TLC of mFG5, mFG6, mFG7 and mFG8 ran 
with a 10:2.7:2 ethyl acetate: methanol: water solvent system 
developed with the ferric chloride spray reagent to test for 
the presence of phenolics. The development of a green or 
brown color is a positive test for the presence phenolics. 
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A better solvent system was discovered to more clearly separate the compounds in fractions 
mFG5-mFG8, which was an ethyl acetate: methanol: water (10:7:2) solvent. Since the mFG7 
fraction gave the highest yield in of extract in grams, it was examined again for the presence of 
phenolic compounds using the ferric chloride spray reagent to see if all of the components were 
phenolic in nature when spread out (Figure 19. 
 
 
Figure 19. A diagnostic test for the presence of phenolics was performed by spraying a Ferric 
Chloride spray reagent on a TLC of mFG7 using an ethyl acetate: methanol: water (10:7:2) solvent 
system. The development of a greenish color denotes a compound phenolic in nature. The right TLC 
shows mFGcons under short wavelength UV. Dotted lines indicate the spots in mFG7 that correlate 
with the compounds present in mFGcons. 
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Since the majority of the spots on the TLC of mFG7 gave a positive on the ferric chloride 
test, the estrogenic activity is likely associated with compounds that are phenolic in nature. This 
result strongly suggests that one of those phenolics, or more, are linked with the estrogenic activity 
associated with mFGcons. Isoflavones are the known phenolic compounds that possess estrogenic 
activity (Messina & Wood, 2008). Therefore, one hypothesis is that the estrogenically active 
compounds in mFGcons are estrogenic isoflavones. 
Subsequently, fractions mFG6, mFG7 and mFG8 were consolidated based on the similarity 
of their chemical composition, as shown in Figure 17, to produce a sample that contained the 
compound(s) exhibiting estrogenic activity. The consolidated fraction (mFGcons) was examined 
on a silica gel TLC with many different solvent systems. The solvent system that best separated 
the compound in mFGcons was found to be an ethyl acetate: methanol: water (10:7:2) solvent 
system. A preparative TLC was then used to separate the components in the mFGcons extract. The 
preparative TLC of mFGcons yielded four samples, mFG-I, mFG-II, mFG-III, mFG-IV. The TLC 
in Figure 20 shows the samples in relation to the mFGcons. As seen in the TLC, five distinct 
compounds can be visualized on the TLC plate (A,B,C,D and E). 
The estrogenic activity of the four samples, mFG-I, mFG-II, mFG-III and mFG-IV, was 
then measured. The samples reported 0.66 Miller units/sample, 0.902 Miller units/sample, 0 Miller 
units/sample and 0.47 Miller units/sample of estrogenic activity respectively. The samples were 
standardized to similar concentrations before the assay. As was the case before, since such minute 
amounts of a sample are being dealt with, it is important to keep in mind that errors may arise from 
the limitations of the mass spec.  Results are shown in Figure 21. Since mFG-III, which contains 
compounds C and D, did not report any estrogenic activity, yet mFG-II and mFG-IV did, it can be 
deduced that neither compound C nor D possess estrogenic activity while compounds A, B, and E 
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do report estrogenic activity. This leaves compounds A, B and E estrogenically active, and hence, 
to be phytoestrogens.  
 
  
A 
B 
C 
D 
E 
mFGcons mFG-I 
(+) 
 
mFG-II 
(+) 
 
mFG-III 
(-) 
 
mFG-IV 
(+) 
 
Figure 20. A silica gel TLC of mFGcons, mFG-I, mFG-II, mFG-
III and mFG-IV separated using an ethyl acetate: methanol: water 
(10:7:2) solvent system shown under long wavelength UV light. 
Five distinct compounds can be identified in the separation of the 
fractions, which are labeled A-E. The fractions with (+) tested 
positive for estrogenic activity, while the fraction with (-) tested 
negative for estrogenic activity. 
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There is strong evidence to suggest that these phytoestrogens are isoflavones. The 
compounds were confirmed to be phenolic in nature using the ferric chloride diagnostic test and 
fenugreek contains several flavonoids like vitexin, tricin, naringenin, quercetin, kaempferol and 
luteolin (Parthasarathy et al., 2008). Furthermore, analysis of samples using mass spectrometry 
indicated the presence of multiple isoflavones. The total ion chromatogram acquired in the 
negative mode for CMFG (Figure 22) shows peaks at m/z = 253.30, 285.50 and 297.40 amu, which 
suggests the presence of several isoflavones. The hypothesized isoflavones are shown in Figure 
23. Note that all isoflavones have the capacity to lose a hydrogen and become negatively charged. 
Therefore, in the negative mode of the mass spectrometry, the molecular weight is 1g/mol less 
than its actual molecular weight. By a comparative process of elimination based on the total ion 
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Figure 21. Estrogenic activity of mFG-I, mFG-II, mFG-III and mFG-IV 
compared to the estradiol standard and mFGcons. Activity is reported in 
Miller untis. 
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chromatogram (TIC) for the four samples and their estrogenic activity, a group of molecular ion 
peaks are concluded to be the active principles. For example, mFG-II is the most active sample. 
Figure 24 shows the TIC of the sample and the molecular ion peaks of m/z 281.2 and 283.2 which 
have been tentatively identified as 5-hydroxy-6,7-methylenedioxyflavone and Biochanin A 
respectively. (Figure 25). Biochanin A has been previously isolated form Fenugreek, but never 
associated with estrogenic activity (Wang et al. 2010). 
 
 
 
Figure 22. Total Ion Chromatogram TIC of CMFG extract. 
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Figure 23. Isoflavones that may be present in fenugreek according to the m/z 
peaks of the total ion chromatogram of the CMFG extract 
 
Daidzein 
Molecular weight: 254.2375 g/mol 
Corresponds to 253.30 m/z peak 
 
8-Hydroxygenistein 
Molecular weight: 286.2363 g/mol 
Corresponds to 285.50 m/z peak 
 
Irilone 
Molecular weight: 298.247 g/mol 
Corresponds to 297.40 m/z peak 
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Figure 24. The Total Ion Chromatogram of mFG-II in the Negative Ion Mode Infusion 
MS Spectrum. 
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Biochanin A 
Molecular weight: 284.26348 g/mol 
Corresponds to 283.2 m/z peak 
 
 
 
 
Further evidence of the presence of isoflavones in fenugreek comes from the UV 
spectrum of mFGcons. As shown in Figure 26, the peaks of the compounds in mFGcons are 
within the range of typical peaks found in the UV spectrum of isoflavones. For example, the 
peaks for Biochanin A dissolved in methanol are 261 and 330nm (Mabry et al. 1970).  
 
 
Figure 26. The UV spectra of mFGcons. 
 
A model to explain the capacity of isoflavones to mimic the hormonal properties of 
estradiol has been proposed in the literature and shown in Figure 27 and 28. According to this 
Figure 25. The structures of the tentatively identified isoflavones in mFG-
II. Biochanin A corresponds to the m/z value of 283.2 from the mFG-II TIC. 
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model, the structural similarity of isoflavones to estrogen is what enables isoflavones to exhibit 
estrogenic activity via the human estrogen receptor. Additionally, fenugreek belongs to the 
Fabaceae family, which synthesize isoflavones. Isoflavones are found exclusively in this family 
because the plants belonging to this family possess the enzyme responsible for transforming 2-
phenylchroman to 3-phenylchroman, a necessary step in isoflavone production (Hanganu et al. 
2010). Soy, which contains the estrogenically active isoflavones genistein, daidzein and glycitein, 
belongs to this family.  
 
   
 
 
 
Figure 27. The structural similarity of isoflavones to estrogen. 
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The results of this investigation suggest that in addition to diosgenin, non-steroidal estrogen 
mimics are present in fenugreek, which have never been previously reported. These additional 
estrogen mimics in fenugreek appear to be a family of isoflavones recurrent in the Fabaceae 
family. Although their relative concentrations appear to be low, since isoflavones act as 
hormones, trace amounts are sufficient to elicit a response. 
 
 
 
 
 
 
 
Figure 28. A pictorial depiction of the binding of 
estrogen compared with isoflavones to the estrogen 
receptor.  
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Chapter 2 
Acetylcholinesterase Inhibition 
I. Introduction 
One of the leading dementia pathologies is Alzheimer’s disease (AD), which affects over 
50 percent of dementia patients (Howes & Perry, 2011). Alzheimer’s disease is a devastating 
disease that causes memory loss, especially the formation of new memories, and impairs 
cognition like language and social skills. Currently, an estimated 44 million people are diagnosed 
with AD, and this figure is expected to grow to 100 million people by 2050 (Thies & Bleiler, 
2013). Although the number of people affected by AD is increasing rapidly, there is still no cure 
for the disease and the mechanism of action of the disease largely remains a mystery. Evidence 
has shown that genetics play a role in the development of AD. Of the two types of AD, early-
onset and late-onset, early-onset AD is mostly inherited (Alzheimer’s Disease Education and 
Referral (ADEAR) Center, 2011). However, early-onset AD represents less than 5 percent of all 
AD cases.  
One hypothesis on the pathological mechanism of Alzheimer’s disease is cholinergic 
system degeneration (Howes & Perry, 2011). Decreases in biochemical indices of cholinergic 
function in the neocortex and hippocampus have been found to be correlated with the severity of 
dementia. Cholinesterases are a family of enzymes that catalyze the hydrolysis of the 
neurotransmitter acetylcholine (ACh) into choline and acetic acid. This reaction is necessary for 
cholinergic neurons to return to their resting state (Colovic et al. 2013). The cholinesterase most 
targeted in AD is Acetylcholinesterase. As shown in Figure 1, acetylcholinesterase breaks down 
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acetylcholine in the synaptic cleft. Therefore, inhibition of this enzyme increases the level and 
duration of acetylcholine’s action as a neurotransmitter (Colovic et al. 2013). 
 
 
 
 
 
Figure 1. The mechanism of action of choline acetyl 
transferase. (The Lundbeck Institute, 2014) 
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Acetylcholinesterase (AChE) inhibitors have been proven to improve cognitive and 
neuropsychiatric symptoms over at least 6 months in patients with mild to moderate AD 
(Natarajan et al. ,2013). There are currently three different AChE inhibitors prescribed to AD 
patients, donepezil, rivastigmine and galantamine, all of which are reversible AChE inhibitors 
(Colovic et al. 2013). However, these drugs have limitations due to their short half-lives and 
undesirable side effects such as hepatotoxicity and gastrointestinal diseases. Although AChE 
inhibitors inhibit the same enzyme, they are structurally diverse (Brufani & Filocamo, 2000). 
Their structural diversity has led to an interest in finding better cholinesterase inhibitors, 
especially from natural products (Sung et al. 2002). 
One popular natural product that has long been used as a cognitive enhancer in Chinese 
traditional medicine is Ginkgo biloba L. (Ginkgoaceae), which has the most mechanistic and 
clinical data relevant to dementia than any other plant species (Perry & Howes, 2011). Despite 
contradicting reviews on G. biloba’s effect on cognition, G. biloba does show a dose dependent 
effect on AChE inhibition activity (Suganthy et al. 2013). G. biloba is an appealing natural 
product for treating dementia, like AD, because it has few indications of significant side effects 
(Perry & Howes, 2011). There are several different compounds that act as AChE inhibitors found 
in plants, like alkaloids, glycosides, and xanthones, and there is a lot of current interest in 
discovering new compounds with minimal side effects for therapeutic purposes (Suganthy et al. 
2013).  
Fenugreek, or Trigonella foenum graecum L. (Fabaceae) has shown potential for AChE 
inhibition, which is thought to be associated with the simple alkaloid Trigonelline (Suganthy et al. 
2013). One study found AChE inhibition activity in a hydro alcoholic extract, ethyl acetate 
fraction, chloroform fraction and alkaloid fraction of Fenugreek using Ellman’s method and TLC 
48 
 
bioassay detection (SatheeshKumar et al. 2010). In addition, there are other plants in the Fabaceae 
family that have promising AChE inhibitory activity. Physostigma venenosum L. (Fabaceae), 
commonly known as the calabar bean, showed AChE inhibitory activity from the compound 
physostigmine isolated from its seeds. Physostigmine is an indole alkaloid that has been approved 
by the FDA to treat mild to moderate AD, and is present in the formulation Synapton® (Suganthy 
et al. 2013). 
However, despite multiple studies that report AChE inhibition activity in fenugreek, there 
is no conducive evidence of the chemistry associated with it. The aim of this study is to assess 
AChE inhibition activity in fenugreek extracts to see whether or not there are multiple compounds 
possessing AChE inhibitory activity in fenugreek, and to possibly establish the chemical identity 
of these compounds. The AChE inhibition activity was evaluated using a bioautographic method 
described in the literature. 
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II. Materials and Methods 
i.  Acetylcholinesterase Inhibition Activity Assay 
1000 U of Acetylcholinesterase were dissolved in 149 mL of Buffer A solution (50 mM 
Tris-Hydrochloric acid buffer at pH 7.8) to have a solution of 6.7 U/mL of enzyme. The Fenugreek 
extracts were loaded onto the silica TLC plates and developed with a solvent solution of ethyl 
acetate:methanol:water (10:2.7:1) or appropriate mixture for optimal separation. After running the 
TLC, the plate was dried completely (with a blow dryer) before 2mL of the enzyme solution was 
sprayed onto the plate. The enzyme solution was at room temperature (~21°C) at the time of 
application. After completely spraying the enzyme solution onto the plate, the plate was dried again 
and then placed in a small, covered plastic container and then placed to incubate at 37°C for twenty 
minutes. The plastic container contained a small amount of water in it just enough to wet the bottom 
of the container so that the atmosphere within the chamber was humid. The container contained a 
layer of material to separate the water from the TLC plate. 
After twenty minutes of incubation, the plate was removed from the incubator and dried 
again. To detect enzymatic activity, a 2mL solution of 13.4 mM naphthyl acetate and a 8mL solution 
of 7.4 mM FBS were combined and then sprayed onto the plate. After applying this mixture, the 
plate was then set aside to react in the dark for 12 hours. The plate turned red-purple while active 
fractions (fractions that inhibit Acetylcholinesterase) appeared as white spots (Adhami et al. 2011; 
Marston et al. 2001). 
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III. Results and Discussion 
The Acetylcholinesterase Inhibition Activity Assay was performed on several of the 
Fenugreek extracts using a bioautographic assay that makes use of the AChE on a TLC plate (see 
Figure 1). Results of the assays are shown in the following Figures 2-4, where the white spots 
indicate compounds that inhibit the AChE. 
 
 
 
 
Figure 1. A schematic of the bioautographic assay used to 
screen the fenugreek extracts for acetylcholinesterase 
inhibition activity. 
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As shown in Figure 2, the HFG extract contains a compound at an Rf value of 0.87 that 
shows significant AChE activity by the area of discoloration, where there is lack in development 
of the purple-red background. These areas of discoloration indicate the presence of an AChE 
inhibitor, blocking the formation of 1-naphtol, which reacts with the fast blue salt to give a 
purple-red colored diazonium dye (Marston et al. 2002). The TLC from the bioautographic AChE 
inhibition assay is compared with a TLC of the HFG extract viewed with short UV light to show 
that the compound possessing AChE inhibition activity in the HFG extract is presumably the 
main compound present in this extract. Attempts to acquire the electrospray ionization mass 
spectrum (ESIMS) of this compound were unsuccessful as the solvent was too volatile to yield the 
molecular ion suitable for analysis, although the effort to identify the compound was made. 
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The CMFG extract showed two prominent zones of inhibition with Rf values of 0.5 and 
0.91. The partition of CMFG into the chloroform and methanol soluble fractions resulted in the 
separation of these two AChE inhibitors. The compound with the Rf of 0.91 partitioned into the 
chloroform soluble fraction and the compound with an Rf of 0.5 partitioned into the methanol 
Figure 2. On the left, an Acetylcholinesterase Inhibition Activity Assay 
performed on a TLC with HFG, CMFG, cFG, mFG and mFG6 extracts 
applied (from left to right) using an ethyl acetate: methanol: water 
(10:2.7:2) solvent system. On the right, a TLC of HFG, CMFG and AEFG 
(from left to right) viewed under short wavelength UV light. 
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soluble fraction. Additionally, the methanol soluble fraction showed a zone of inhibition between 
an Rf of 0.2 and 0.4 where more than one AChE inhibitor might be present. 
Fractions 1-8 from the Sephadex LH-20 column chromatography of the methanol soluble 
fraction were assayed for AChE inhibition activity (Figure 3). The assay revealed the presence of 
some active components. The compounds with AChE inhibition activity in fractions mFG6 and 
mFG7 are of particular interest to the investigation of fenugreek because they appear to be present 
in the same fractions that are described to possess estrogenic activity in Chapter 1. For further 
investigation, the bioautographic assay for AChE inhibition was performed on the consolidated 
mFG6, mFG7 and mFG8 fractions (mFGcons, Figure 4).  
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Figure 3. Acetylcholinesterase Inhibition Activity Assay performed on a 
TLC with mFG and mFG1- mFG8 extracts applied (from left to right) 
using an ethyl acetate: methanol: water (10:2.7:2) solvent system. Arrows 
show areas of enzyme inhibition. 
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From the analysis of the TLC in Figure 4, there are three compounds in mFGcons with 
AChE inhibition activity that are primarily associated with the mFG-I and mFG-II samples from 
preparative TLC. Of the compounds, A, B and C, compounds A and B possess estrogenic activity. 
Figure 4. On the left, an acetylcholinesterase inhibition 
activity assay performed on a TLC of the mFGcons extract 
using an ethyl acetate: methanol: water (10:5:2) solvent 
system. On the right, a TLC of mFG, mFG-I, mFG-II, mFG-
III and mFG-IV is shown (solvent system of ethyl acetate: 
methanol: water 10:7:2) under short wavelength UV. Arrows 
depict the identified compounds A-E from short wavelength 
TLC that exhibit AChE inhibition activity. Compounds A,B 
and C are presumably the same on each TLC because of their 
similar Rf values. 
A 
B 
C 
D 
C 
E 
56 
 
These results suggest that possibly the same isoflavones are also responsible for the AChE 
inhibition activity. 
This would not be the first plant to possess isoflavones with acetylcholinesterase 
inhibition activity. Venzke et al. identified four isoflavones (3′,4′-dihydroxy-6″,6″,6″′,6″′-
tetramethylbis pyrano[2″,3″:5,6::2″′,3″′:7,8] isoflavone, 3′,4′-dimethoxy- 5-hydroxy-6 ″ , 6 ″ -
dimethylpyrano[2 ″ , 3 ″ :7,6] isoflavone, 3′-methoxy-5,4′-dihydroxy-6″,6″- 
dimethylpyrano[2″,3″:7,6]isoflavone, 5,3′,4′-trihydroxy-6″,6″-dimethylpyrano[2″,3″:7,6] 
isoflavone)  as AChE inhibitors from Polygala molluginifolia (2013). However, there is scarce 
literature on other isoflavones that have been explored for AChE inhibition activity. 
Furthermore, there are no studies that have yielded compounds to be both estrogenic and 
AChE inhibitory. Nevertheless, several plants in the Fabaceae family report improving memory 
and dementia in ethnobotanical records (Adams et al. 2007). Such is the case for Medicago sativa 
L., Barbieria pinnata, Glycyrrhiza glabra L. and several others. Therefore, it is not surprising that 
fenugreek possesses AChE inhibitory activity as well. 
The finding that isoflavones in fenugreek contain both estrogenic and AChE inhibition 
activity requires further investigation. However, this study suggests that this is the case and opens 
the potential for medicinal uses of these isoflavones in the treatment of Alzheimer’s, in addition 
to hormone replacement therapy. Despite estrogen’s extensive involvement in the nervous system, 
no literature reports estrogen as an AChE inhibitor. Although this is all speculation, it may be 
worthwhile to investigate estrogen and its mimics for AChE inhibition activity.  
The discovery of these phytoestrogens as AChE inhibitors also raises the question as to 
whether or not current AChE inhibitory drugs possess estrogenic activity. This could have 
profound implications for the side effects, which could be beneficial or negative, of AChE 
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inhibition drugs. This novel discovery in fenugreek could present an avenue for the synthetic 
production of drugs that are used to treat both Alzheimer’s and have estrogenic activity, which 
elicits numerous physiological effects. 
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